Novel Latency Reversal Agents for HIV-1 Cure

Annual Review of Medicine

Volumn 69, Issue , 2018, Pages 421-436

  Spivak, Adam M ^a   Planelles, Vicente ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Benzotriazole; Disulfiram; HIV 1 reservoir; Ingenol; Latency reversal agents; NF B; Protein kinase C; Shock and kill; SMAC; STAT5; Viral latency

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOTRIAZOLE DERIVATIVE; CYTOKINE; DISULFIRAM; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR AGONIST; ALDEHYDE DEHYDROGENASE INHIBITOR; IMMUNOLOGICAL ADJUVANT; PROTEIN KINASE C; TOLL LIKE RECEPTOR;

ANTIRETROVIRAL THERAPY; CYTOKINE RESPONSE; DEACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRUS LATENCY; VIRUS REACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; VIRUS ACTIVATION;

ACETALDEHYDE DEHYDROGENASE INHIBITORS; ADJUVANTS, IMMUNOLOGIC; DISULFIRAM; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; PROTEIN KINASE C; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 85041712062     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-052716-031710     Document Type: Review

References (110)

1. Chun TW, Stuyver L, Mizell SB, et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. PNAS 94:13193-97
2. Finzi D, Hermankova M, Pierson T, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-300 www.annualreviews.org Latency Reversal for HIV-1 Cure 431
3. Wong JK, Hezareh M, Gunthard HF, et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-95
4. Finzi D, Blankson J, Siliciano JD, et al. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat.Med. 5:512-17
5. Siliciano JD, Kajdas J, Finzi D, et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-28
6. Whitney JB, Hill AL, Sanisetty S, et al. 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74-77
7. Strain MC, Little SJ, Daar ES, et al. 2005. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191:1410-18
8. Eriksson S, Graf EH, Dahl V, et al. 2013. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLOS Pathog. 9:e1003174
9. Crooks AM, Bateson R, Cope AB, et al. 2015. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. 212:1361-65
10. Dinoso JB, Kim SY,Wiegand AM, et al. 2009. Treatment intensification does not reduce residualHIV-1 viremia in patients on highly active antiretroviral therapy. PNAS 106:9403-8
11. Gandhi RT,CoombsRW,ChanES, et al. 2012.Noeffect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59:229-35
12. Gandhi RT, Zheng L, Bosch RJ, et al. 2010. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLOS Med. 7(8):e1000321
13. Richman DD, Margolis DM, Delaney M, et al. 2009. The challenge of finding a cure for HIV infection. Science 323:1304-7
14. Choudhary SK, Margolis DM. 2011. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51:397-418
15. Ruelas DS, GreeneWC. 2013. An integrated overview of HIV-1 latency. Cell 155:519-29
16. Xing S, Siliciano RF. 2013. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov. Today 18:541-51
17. Margolis DM. 2014. How might we cure HIV? Curr. Infect. Dis. Rep. 16:392
18. Martin AR, Siliciano RF. 2016. Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure. Annu. Rev. Med. 67:215-28
19. Deeks SG. 2012. HIV: shock and kill. Nature 487:439-40
20. Delagreverie HM, Delaugerre C, Lewin SR, et al. 2016. Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents. Open Forum Infect. Dis. 3:ofw189
21. Spivak AM, Planelles V. 2016. HIV-1 eradication: early trials (and tribulations). TrendsMol.Med. 22:10-27
22. Zack JA, Arrigo SJ,Weitsman SR, et al. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-22
23. Perelson AS, Essunger P, Cao Y, et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-91
24. Kulkosky J, Nunnari G, Otero M, et al. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-11
25. Prins JM, Jurriaans S, van Praag RM, et al. 1999. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-10
26. Spina CA, Anderson J, Archin NM, et al. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLOS Pathog. 9:e1003834
27. Bullen CK, Laird GM, Durand CM, et al. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20:425-29
28. Laird GM, Bullen CK, Rosenbloom DI, et al. 2015. Ex vivo analysis identifies effective HIV-1 latencyreversing drug combinations. J. Clin. Investig. 125:1901-12
29. McKernan LN, Momjian D, Kulkosky J. 2012. Protein kinase C: one pathway towards the eradication of latent HIV-1 reservoirs. Adv. Virol. 2012:805347
30. Jiang G, Dandekar S. 2015. Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res. Hum. Retrovir. 31(1):4-12
31. Castagna M, Takai Y, Kaibuchi K, et al. 1982. Direct activation of calcium-activated, phospholipiddependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257:7847-51
32. Nishizuka Y. 1984. The role of protein kinaseCin cell surface signal transduction and tumour promotion. Nature 308:693-98
33. Zayed S, Hafez A, Adolf W, Hecker E. 1977. New tigliane and daphnane derivatives from Pimelea prostrata and Pimelea simplex. Experientia 33:1554-55
34. Gustafson KR, Cardellina JH2nd,McMahon JB, et al. 1992. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J. Med. Chem. 35:1978-86
35. Kulkosky J, Culnan DM, Roman J, et al. 2001. Prostratin: activation of latentHIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98:3006-15
36. Kulkosky J, Sullivan J, Xu Y, et al. 2004. Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res. Hum. Retrovir. 20:497-505
37. Williams SA, Chen LF, Kwon H, et al. 2004. Prostratin antagonizes HIV latency by activating NF-κB. J. Biol. Chem. 279:42008-17
38. PettitGR, Kamano Y, Fujii Y, et al. 1981. Marine animal biosynthetic constituents for cancer chemotherapy. J. Nat. Prod. 44:482-85
39. Smith JB, Smith L, Pettit GR. 1985. Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem. Biophys. Res. Commun. 132:939-45
40. Kollar P, Rajchard J, Balounova Z, Pazourek J. 2014. Marine natural products: bryostatins in preclinical and clinical studies. Pharm. Biol. 52:237-42
41. Philip PA, Rea D, Thavasu P, et al. 1993. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. 85:1812-18
42. Gutierrez C, Serrano-Villar S, Madrid-Elena N, et al. 2016. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30:1385-92
43. Ernst M, Grace OM, Saslis-Lagoudakis CH, et al. 2015. Global medicinal uses of Euphorbia L. (Euphorbiaceae). J. Ethnopharmacol. 176:90-101
44. Kupchan SM, Uchida I, Branfman AR, et al. 1976. Antileukemic principles isolated from euphorbiaceae plants. Science 191:571-72
45. Fujiwara M, Ijichi K, Tokuhisa K, et al. 1996. Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob. Agents Chemother. 40:271-73
46. Warrilow D, Gardner J, Darnell GA, et al. 2006. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res. Hum. Retrovir. 22:854-64
47. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, et al. 2014. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 462-463:328-39
48. AbreuCM, Price SL, Shirk EN, et al. 2014. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLOS ONE 9:e97257
49. Alchin DR. 2014. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol. Ther. 4:157-64
50. Jiang G,Mendes EA, Kaiser P, et al. 2015. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-κB signaling in combination with JQ1 induced p-TEFb activation. PLOS Pathog. 11:e1005066
51. Gama L, Abreu CM, Shirk EN, et al. 2017. Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS 31:5-14
52. Dental C, Proust A, Ouellet M, et al. 2017. HIV-1 latency-reversing agents prostratin and bryostatin-1 induce blood-brain barrier disruption/inflammation and modulate leukocyte adhesion/transmigration. J. Immunol. 198:1229-41
53. Shi QW, Su XH, Kiyota H. 2008. Chemical and pharmacological research of the plants in genus Euphorbia. Chem. Rev. 108:4295-327 www.annualreviews.org Latency Reversal for HIV-1 Cure 433
54. Cary DC, Fujinaga K, Peterlin BM. 2016. Euphorbia kansui reactivates latent HIV. PLOS ONE 11:e0168027
55. Hamer DH, Bocklandt S, McHugh L, et al. 2003. Rational design of drugs that induce human immunodeficiency virus replication. J. Virol. 77:10227-36
56. MarquezN, CalzadoMA, Sanchez-Duffhues G, et al. 2008. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem. Pharmacol. 75:1370-80
57. Jiang G, Mendes EA, Kaiser P, et al. 2014. Reactivation of HIV latency by a newly modified ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS 28:1555-66
58. Spivak AM, Larragoite ET, Coletti ML, et al. 2016. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology 13:88
59. Martin AR, Pollack RA, Capoferri A, et al. 2017. Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J. Clin. Investig. 127:651-56
60. Besnard E, Hakre S, Kampmann M, et al. 2016. The mTOR Complex Controls HIV latency. Cell Host Microbe 20:785-97
61. Cillo AR, Sobolewski MD, Bosch RJ, et al. 2014. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. PNAS 111:7078-83
62. Archin NM, Liberty AL, Kashuba AD, et al. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-85
63. Elliott JH, Wightman F, Solomon A, et al. 2014. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLOS Pathog. 10:e1004473
64. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-21
65. Rasmussen TA, Tolstrup M, Moller HJ, et al. 2015. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect. Dis. 2:ofv037
66. Sogaard OS, Graversen ME, Leth S, et al. 2015. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLOS Pathog. 11:e1005142
67. Rasmussen TA, Tolstrup M, Sogaard OS. 2016. Reversal of latency as part of a cure for HIV-1. Trends Microbiol. 24:90-97
68. Xing S, Bullen CK, Shroff NS, et al. 2011. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 85:6060-64
69. DoyonG, Zerbato J, Mellors JW, Sluis-CremerN. 2013. Disulfiram reactivates latentHIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 27:F7-F11
70. Spivak AM, Andrade A, Eisele E, et al. 2014. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58:883-90
71. Elliott JH, McMahon JH, Chang CC, et al. 2015. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2:e520-29
72. Medzhitov R. 2007. TLR-mediated innate immune recognition. Semin. Immunol. 19:1-2
73. KumarH, Kawai T, Akira S. 2011. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30:16-34
74. Thibault S, Imbeault M, Tardif MR, Tremblay MJ. 2009. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells. Virology 389:20-25
75. Novis CL, Archin NM, Buzon MJ, et al. 2013. Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation. Retrovirology 10:119
76. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58-65
77. Bosque A, Nilson KA, Macedo AB, et al. 2017. Benzotriazoles reactivate latent HIV-1 through inactivation of STAT5 SUMOylation. Cell Rep. 18:1324-34
78. Van Nguyen T, Angkasekwinai P, Dou H, et al. 2012. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol. Cell 45:210-21
79. Selliah N, ZhangM, DeSimone D, et al. 2006. The γc-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology 344:283-91
80. Sun SC. 2011. Non-canonical NF-κB signaling pathway. Cell Res. 21:71-85
81. Pache L,Dutra MS, Spivak AM, et al. 2015. BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe 18:345-53
82. Archin NM, Bateson R, Tripathy MK, et al. 2014. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J. Infect. Dis. 210:728-35
83. Martinez-Bonet M, Clemente MI, Serramia MJ, et al. 2015. Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and bryostatin-1. Sci. Rep. 5:16445
84. Darcis G, Kula A, Bouchat S, et al. 2015.Anin-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. PLOS Pathog. 11:e1005063
85. Reuse S, Calao M, Kabeya K, et al. 2009. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLOS ONE 4:e6093
86. Brogdon J, ZianiW,Wang X, et al. 2016. In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. Sci. Rep. 6:39032
87. Chen D, Wang H, Aweya JJ, et al. 2016. HMBA enhances prostratin-induced activation of latent HIV-1 via suppressing the expression of negative feedback regulator A20/TNFAIP3 in NF-κB signaling. Biomed. Res. Int. 2016:5173205
88. Rochat MA, Schlaepfer E, Speck RF. 2017. Promising role of toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV. J. Virol. 91(4):e02084-16
89. Klase Z, Yedavalli VS, Houzet L, et al. 2014. Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA. PLOS Pathog. 10:e1003997
90. Bouchat S, Delacourt N, Kula A, et al. 2016. Sequential treatment with 5-aza-2-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO. Mol. Med. 8:117-38
91. Abdel-Mohsen M, Chavez L, Tandon R, et al. 2016. Human galectin-9 is a potent mediator of HIV transcription and reactivation. PLOS Pathog. 12:e1005677
92. Shan L,DengK, ShroffNS, et al. 2012. Stimulation ofHIV-1-specific cytolyticTlymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501
93. Jones RB, Walker BD. 2016. HIV-specific CD8+ T cells andHIV eradication. J. Clin. Investig. 126:455-63
94. Jones RB, O'Connor R, Mueller S, et al. 2014. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLOS Pathog. 10:e1004287
95. CluttonG, Xu Y, Baldoni PL, et al. 2016. The differential short-and long-term effects of HIV-1 latencyreversing agents on T cell function. Sci. Rep. 6:30749
96. Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. 2016. The effect of latency reversal agents on primary CD8+ T cells: implications for shock and kill strategies for human immunodeficiency virus eradication. EBioMedicine 8:217-29
97. Kwaa AK,Goldsborough K,Walker-Sperling VE, et al. 2017. The effect of ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells. PLOS ONE 12:e0174516
98. Pace M, Williams J, Kurioka A, et al. 2016. Histone deacetylase inhibitors enhance CD4 T cell susceptibility to NK cell killing but reduce NK cell function. PLOS Pathog. 12:e1005782
99. Garrido C, Spivak AM, Soriano-SarabiaN, et al. 2016. HIV latency-reversing agents have diverse effects on natural killer cell function. Front. Immunol. 7:356
100. Leth S, Schleimann MH, Nissen SK, et al. 2016. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Lancet HIV 3:e463-72
101. Mylvaganam GH, Silvestri G, Amara RR. 2015. HIV therapeutic vaccines: moving towards a functional cure. Curr. Opin. Immunol. 35:1-8
102. Eisele E, Siliciano RF. 2012. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377-88
103. Jin H, Li D, Sivakumaran H, et al. 2016. Shutdown of HIV-1 transcription in T cells by Nullbasic, a mutant Tat protein. MBio 7(4):e00518-16 www.annualreviews.org Latency Reversal for HIV-1 Cure 435
104. Cupelli LA, Hsu MC. 1995. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J. Virol. 69:2640-43
105. Mousseau G, Kessing CF, Fromentin R, et al. 2015. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. MBio 6:e00465
106. Mousseau G, Clementz MA, Bakeman WN, et al. 2012. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe 12:97-108
107. Campos N, Myburgh R, Garcel A, et al. 2015. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology 12:30
108. Lederman MM, Cannon PM, Currier JS, et al. 2016. A cure for HIV infection: "not in my lifetime" or "just around the corner"? Pathog. Immun. 1:154-64
109. Stevenson M. 2017. HIV persistence in macrophages. Nat. Med. 23:538-39
110. Li JZ, Smith DM, Mellors JW. 2015. The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS 29:1429-32